Confirmatory Results

Commitments by the biopharmaceutical industry to clinical trials transparency: the evolving environment

Slavka Baronikova, Jim Purvis, Eric Southam, Julie Beeso, Christopher Winchester, Antonia Panayi
doi: https://doi.org/10.1101/349902

Article Information

doi 
https://doi.org/10.1101/349902
History 
  • November 12, 2018.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Slavka Baronikova1 (sbaronikova-c{at}shire.com),
  2. Jim Purvis2,3 (jim.purvis{at}pharmagenesis.com),
  3. Eric Southam2 (eric.southam{at}pharmagenesis.com),
  4. Julie Beeso2 (eric.southam{at}pharmagenesis.com),
  5. Christopher Winchester2 (eric.southam{at}pharmagenesis.com) and
  6. Antonia Panayi1 (apanayi{at}shire.com)
  1. 1 Shire International GmbH;
  2. 2 Oxford PharmaGenesis
  1. ↵* Corresponding author; email: jim.purvis{at}pharmagenesis.com
Back to top
Posted November 12, 2018.
Download PDF
Email
Commitments by the biopharmaceutical industry to clinical trials transparency: the evolving environment
Slavka Baronikova, Jim Purvis, Eric Southam, Julie Beeso, Christopher Winchester, Antonia Panayi
bioRxiv 349902; doi: https://doi.org/10.1101/349902
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools

Subject Area